Relative factors by segment
Each segment is a separate regression; the factor is added to the beneficiary's demographic factors and other categories, then normalized and reduced by the coding intensity adjustment before it meets the plan's base rate. A factor of 1.000 equals the expected cost of an average beneficiary.
| Segment | Model code | Relative factor |
|---|---|---|
| Community, non-dual, aged | CNA_HCC17 | 4.209 |
| Community, non-dual, disabled | CND_HCC17 | 3.995 |
| Community, full-benefit dual, aged | CFA_HCC17 | 3.896 |
| Community, full-benefit dual, disabled | CFD_HCC17 | 4.235 |
| Community, partial-benefit dual, aged | CPA_HCC17 | 3.946 |
| Community, partial-benefit dual, disabled | CPD_HCC17 | 4.103 |
| Long-term institutional | INS_HCC17 | 1.952 |
Hierarchy
Hierarchical condition categories pay only the most severe manifestation of a disease. HCC 17 is the most severe category in its hierarchy. When HCC 17 is present it drops HCC 18 (Cancer Metastatic to Bone, Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid), HCC 19 (Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers), HCC 20 (Lung and Other Severe Cancers), HCC 21 (Lymphoma and Other Cancers), HCC 22 (Bladder, Colorectal, and Other Cancers), HCC 23 (Prostate, Breast, and Other Cancers and Tumors), so documenting the less severe condition alongside it adds nothing to payment but still matters for the clinical record.
ICD-10-CM codes that map to HCC 17
78 codes map to this category in the PY2027 initial mapping, concentrated in the C92 (15), C78 (13), C84 (11), C79 (10), C94 (9), C7B (8) code families. CMS built that mapping from codes valid in FY2025 and FY2026, and descriptions are the CMS mapping descriptions. None of these codes was deleted in the October 1, 2026 update.
| ICD-10-CM | Description |
|---|---|
| C77.1 | Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes |
| C77.8 | Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions |
| C78.00 | Secondary malignant neoplasm of unspecified lung |
| C78.01 | Secondary malignant neoplasm of right lung |
| C78.02 | Secondary malignant neoplasm of left lung |
| C78.1 | Secondary malignant neoplasm of mediastinum |
| C78.2 | Secondary malignant neoplasm of pleura |
| C78.30 | Secondary malignant neoplasm of unspecified respiratory organ |
| C78.39 | Secondary malignant neoplasm of other respiratory organs |
| C78.4 | Secondary malignant neoplasm of small intestine |
| C78.5 | Secondary malignant neoplasm of large intestine and rectum |
| C78.6 | Secondary malignant neoplasm of retroperitoneum and peritoneum |
| C78.7 | Secondary malignant neoplasm of liver and intrahepatic bile duct |
| C78.80 | Secondary malignant neoplasm of unspecified digestive organ |
| C78.89 | Secondary malignant neoplasm of other digestive organs |
| C79.00 | Secondary malignant neoplasm of unspecified kidney and renal pelvis |
| C79.01 | Secondary malignant neoplasm of right kidney and renal pelvis |
| C79.02 | Secondary malignant neoplasm of left kidney and renal pelvis |
| C79.31 | Secondary malignant neoplasm of brain |
| C79.32 | Secondary malignant neoplasm of cerebral meninges |
| C79.40 | Secondary malignant neoplasm of unspecified part of nervous system |
| C79.49 | Secondary malignant neoplasm of other parts of nervous system |
| C79.70 | Secondary malignant neoplasm of unspecified adrenal gland |
| C79.71 | Secondary malignant neoplasm of right adrenal gland |
| C79.72 | Secondary malignant neoplasm of left adrenal gland |
| C7B.00 | Secondary carcinoid tumors, unspecified site |
| C7B.01 | Secondary carcinoid tumors of distant lymph nodes |
| C7B.02 | Secondary carcinoid tumors of liver |
| C7B.03 | Secondary carcinoid tumors of bone |
| C7B.04 | Secondary carcinoid tumors of peritoneum |
| C7B.09 | Secondary carcinoid tumors of other sites |
| C7B.1 | Secondary Merkel cell carcinoma |
| C7B.8 | Other secondary neuroendocrine tumors |
| C84.10 | Sezary disease, unspecified site |
| C84.11 | Sezary disease, lymph nodes of head, face, and neck |
| C84.12 | Sezary disease, intrathoracic lymph nodes |
| C84.13 | Sezary disease, intra-abdominal lymph nodes |
| C84.14 | Sezary disease, lymph nodes of axilla and upper limb |
| C84.15 | Sezary disease, lymph nodes of inguinal region and lower limb |
| C84.16 | Sezary disease, intrapelvic lymph nodes |
| C84.17 | Sezary disease, spleen |
| C84.18 | Sezary disease, lymph nodes of multiple sites |
| C84.19 | Sezary disease, extranodal and solid organ sites |
| C84.1A | Sezary disease, in remission |
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.01 | Acute myeloblastic leukemia, in remission |
| C92.02 | Acute myeloblastic leukemia, in relapse |
| C92.30 | Myeloid sarcoma, not having achieved remission |
| C92.31 | Myeloid sarcoma, in remission |
| C92.32 | Myeloid sarcoma, in relapse |
| C92.50 | Acute myelomonocytic leukemia, not having achieved remission |
| C92.51 | Acute myelomonocytic leukemia, in remission |
| C92.52 | Acute myelomonocytic leukemia, in relapse |
| C92.60 | Acute myeloid leukemia with 11q23-abnormality not having achieved remission |
| C92.61 | Acute myeloid leukemia with 11q23-abnormality in remission |
| C92.62 | Acute myeloid leukemia with 11q23-abnormality in relapse |
| C92.A0 | Acute myeloid leukemia with multilineage dysplasia, not having achieved remission |
| C92.A1 | Acute myeloid leukemia with multilineage dysplasia, in remission |
| C92.A2 | Acute myeloid leukemia with multilineage dysplasia, in relapse |
| C93.00 | Acute monoblastic/monocytic leukemia, not having achieved remission |
| C93.01 | Acute monoblastic/monocytic leukemia, in remission |
| C93.02 | Acute monoblastic/monocytic leukemia, in relapse |
| C94.00 | Acute erythroid leukemia, not having achieved remission |
| C94.01 | Acute erythroid leukemia, in remission |
| C94.02 | Acute erythroid leukemia, in relapse |
| C94.20 | Acute megakaryoblastic leukemia not having achieved remission |
| C94.21 | Acute megakaryoblastic leukemia, in remission |
| C94.22 | Acute megakaryoblastic leukemia, in relapse |
| C94.40 | Acute panmyelosis with myelofibrosis not having achieved remission |
| C94.41 | Acute panmyelosis with myelofibrosis, in remission |
| C94.42 | Acute panmyelosis with myelofibrosis, in relapse |
| D46.22 | Refractory anemia with excess of blasts 2 |
| E34.00 | Carcinoid syndrome, unspecified |
| E34.01 | Carcinoid heart syndrome |
| E34.09 | Other carcinoid syndrome |
| I31.31 | Malignant pericardial effusion in diseases classified elsewhere |
| J91.0 | Malignant pleural effusion |
| R18.0 | Malignant ascites |
New FY2027 codes in this family (CMS mapping pending)
The October 1, 2026 update created 2 codes for conditions that were previously reported with a code mapping to HCC 17; the FY2027 conversion table names that earlier code in the last column. CMS has not mapped the new codes yet, because the PY2027 initial mapping only covers codes valid in FY2025 and FY2026, so treat their category as pending until CMS posts a mapping that includes FY2027 codes.
| New ICD-10-CM | Description | Previously coded as |
|---|---|---|
| C78.31 | Secondary malignant neoplasm of larynx | C78.39 |
| C78.32 | Secondary malignant neoplasm of pharynx | C78.39 |
Every new and deleted code for FY2027, with its CC level and MS-DRGs, is in the FY2027 ICD-10-CM/PCS code changes report.
What changed from V24
The payment year 2025 mapping carries both models for the same codes. Of the 79 codes it maps to V28 HCC 17, 3 had no V24 payment category (new to payment under V28); the largest source is V24 HCC 8 (Metastatic Cancer and Acute Leukemia) with 57 codes. The V28 community, non-dual, aged factor is 4.209 against 2.659 for V24 HCC 8.
| V24 HCC | V24 category | Codes now in HCC 17 | V24 codes with no V28 HCC | V24 factor (CNA) |
|---|---|---|---|---|
| 8 | Metastatic Cancer and Acute Leukemia | 57 | 0 of 82 | 2.659 |
| 10 | Lymphoma and Other Cancers | 11 | 0 of 595 | 0.675 |
| 12 | Breast, Prostate, and Other Cancers and Tumors | 4 | 0 of 271 | 0.150 |
| 9 | Lung and Other Severe Cancers | 3 | 0 of 110 | 1.024 |
| 46 | Severe Hematological Disorders | 1 | 5 of 95 | 1.372 |
V24 and V28 number their categories independently, so the same diagnosis usually carries a different HCC number in each model. The V24 to V28 crosswalk report lists every category pair, and the glossary explains the 2020 CMS-HCC V24 model and the V28 model that replaced it.
Inpatient groups where these diagnoses land
Appendix B of the v44 MS-DRG Definitions Manual places the codes in this category in the logic of 60 MS-DRGs. The groups with the most shared codes are below; a hospital stay coded with one of these diagnoses groups there when it is the principal diagnosis, or when the DRG's logic uses it as a qualifying secondary diagnosis.
| MS-DRG | Title | Shared codes |
|---|---|---|
| DRG 820 | Lymphoma and Leukemia with Major O.R. Procedures with MCC | 41 |
| DRG 821 | Lymphoma and Leukemia with Major O.R. Procedures with CC | 41 |
| DRG 822 | Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC | 41 |
| DRG 834 | Acute Leukemia with MCC | 24 |
| DRG 835 | Acute Leukemia with CC | 24 |
| DRG 836 | Acute Leukemia without CC/MCC | 24 |
| DRG 837 | Chemotherapy with Acute Leukemia as Secondary Diagnosis or with High Dose Chemotherapy Agent with MCC | 24 |
| DRG 838 | Chemotherapy with Acute Leukemia as Secondary Diagnosis with CC or High Dose Chemotherapy Agent | 24 |
| DRG 839 | Chemotherapy with Acute Leukemia as Secondary Diagnosis without CC/MCC | 24 |
| DRG 850 | Acute Leukemia with Other Procedures | 24 |
Local coverage policies that list these diagnoses
Medicare Administrative Contractors name covered ICD-10-CM codes in the billing and coding articles attached to their LCDs. These policies share the most codes with HCC 17 in the current Medicare Coverage Database export (one policy per topic; overlap counts after each). For the services these policies govern, the same diagnoses are covered indications, so the documentation that supports the category also supports the claim for the service.
- LCD L33459: Computerized Axial Tomography (CT), Thorax · 71 shared codes · Palmetto GBA
- Peripheral Nerve Blocks, LCD L33933 · 71 shared codes · First Coast Service Options, Inc.
- Oral Antiemetic Drugs (Replacement for Intravenous Antiemetics) (L33827) · 68 shared codes · CGS Administrators, LLC; Noridian Healthcare Solutions, LLC
- LCD L33457: Cardiac Radionuclide Imaging · 64 shared codes · Palmetto GBA
- Flow Cytometry, LCD L34037 · 61 shared codes · CGS Administrators, LLC
- L34513 Lab: Flow Cytometry · 59 shared codes · Palmetto GBA
- LCD L33461: Implantable Infusion Pump · 55 shared codes · Palmetto GBA
- Oral Anticancer Drugs, LCD L33826 · 53 shared codes · CGS Administrators, LLC; Noridian Healthcare Solutions, LLC
Where these codes sat in the V22 model
The V28 recalibration renumbered and regrouped categories; this table shows which legacy V22 categories the same ICD-10 codes belonged to, which is the quickest way to reconcile a V22-era HCC gap list with the current model.
| V22 HCC | Codes |
|---|---|
| 8 | 57 |
| 10 | 11 |
| 9 | 3 |
| 12 | 3 |
| 46 | 1 |
Part D: the RxHCC categories of these codes
The same diagnoses feed the RxHCC model, which adjusts Medicare Part D payments. Of the 78 codes in HCC 17, 75 also map to a prescription drug category and 3 carry none; the categories are below, and the RxHCC hub has their 2027 MA-PD, PDP and PACE factors.
| RxHCC | Category | Codes |
|---|---|---|
| RxHCC 19 | Leukemias and Other Hematologic Cancers | 39 |
| RxHCC 18 | Secondary Cancer of Lung, Liver, Brain, and Other Sites | 22 |
| RxHCC 20 | Lung, Kidney, and Other Cancers; Secondary Cancer of Lymph Nodes and Other Sites | 7 |
| RxHCC 17 | Secondary Cancer of Bone and Kidney | 4 |
| RxHCC 22 | Prostate, Breast, Bladder, and Other Cancers and Tumors | 3 |
Capturing and defending the category
A category counts for a payment year when a mapped diagnosis is documented at least once during the data collection year by an acceptable provider type at a face-to-face or audio-video encounter, and when the note shows the condition was monitored, evaluated, assessed or treated. Chronic conditions do not carry forward: a category that is not re-documented in the year drops out of the score, which is why annual wellness visits and problem-list reconciliation are where most recapture happens. Risk adjustment data validation audits sample enrollees and ask for the medical record behind each submitted category; an unsupported category is removed and, under the extrapolation rules, the error rate is applied across the contract. The QuickIntell risk adjustment product surfaces suspected and unsupported categories from the chart, and the HCC hub lists every V28 category with its factor and code count.
For teams evaluating QuickIntell software
Evaluate risk adjustment review software
For teams reviewing documentation across a cohort, explore source evidence, proposed findings, reviewer decisions and audit handoffs. Confirm the program, payment year and model scope during evaluation. A category lookup is not a patient-specific coding or payment determination.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions
Which ICD-10 codes map to HCC 17?
78 ICD-10-CM codes map to HCC 17 in the CMS PY2027 initial mapping, for example C77.1 Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes; C77.8 Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions; C78.00 Secondary malignant neoplasm of unspecified lung; C78.01 Secondary malignant neoplasm of right lung. The full list is on this page; a code counts only when it is documented at a face-to-face or video encounter in the data collection year and supported by the record.
How much does HCC 17 add to a risk score?
The V28 relative factor for HCC 17 is 4.209 for a community, non-dual, aged beneficiary, 3.896 for full-benefit dual aged, 3.995 for non-dual disabled and 1.952 for long-term institutional members. A factor of 1.000 equals the expected annual cost of an average beneficiary, so the category's share of the payment follows the plan's base rate for that segment.
Does HCC 17 count together with related categories?
No. Within a hierarchy only the most severe category is paid. HCC 17 is the most severe category in its hierarchy, and it drops HCC 18, HCC 19, HCC 20, HCC 21, HCC 22, HCC 23 when it is present.
What has to be documented for HCC 17 to be valid?
One of the 78 mapped codes (such as C77.1) must be recorded by an acceptable provider type during a face-to-face or audio-video encounter in the service year, with the note showing that the condition (Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic) was monitored, evaluated, assessed or treated. Risk adjustment data validation audits recover payment for categories the record does not support, so the code on the claim and the assessment in the note must match.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- ICD-10-CM to CMS-HCC V28 mappings, payment year 2027 initialVersion PY2027 initial ICD-10-CM mappings (dates of service 2026) · effective 2027-01-01 · file 2027 Initial ICD-10-CM Mappings.csvSHA-256 9c260b06d0dd2806…
- CMS-HCC V28 model software: labels, hierarchies and relative factorsVersion CMS-HCC V28 software V2826.115.T2 (PY2027 initial) · effective 2027-01-01 · file C2824T2N.csvSHA-256 20f38d537493b41c…
Disclaimer
Relative factors and mappings are reproduced from the CMS risk adjustment model files as an operational reference. Payment depends on the plan's base rate, normalization, the coding intensity adjustment and the enrollee's segment. Not legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.